Abstract PR018: IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors
Martin Wermke(National Center for Tumor Diseases), Jason J. Luke(University of Chicago), Steffen Walter(Universität Ulm), Dejka M. Araujo(The University of Texas MD Anderson Cancer Center), Mamta Kalra, Harpreet Singh(Immatics Biotechnologies (Germany)), Tobias A.W. Holderried(Brigham and Women's Hospital), Sapna P. Patel(JSS Dental College and Hospital), Cedrik M. Britten(Johannes Gutenberg University Mainz), Regina Mendrzyk(Immatics Biotechnologies (Germany)), Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Winfried Alsdorf(Universität Hamburg), Norbert Hilf(Immatics Biotechnologies (Germany)), Manik Chatterjee(University of Würzburg), Ran Reshef(Abramson Cancer Center), Toni Weinschenk(Immatics Biotechnologies (Germany)), Andrea Mayer-Mokler(Immatics Biotechnologies (Germany)), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Ali Mohamed, Arun Satelli(The University of Texas MD Anderson Cancer Center)
Cited by 16
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
|Journal of Clinical Oncology|2018|925
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803